Stock ENBI ENTHEON BIOMEDICAL CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Entheon Biomedical Corp.

Equities

ENBI

CA29383X2023

Biotechnology & Medical Research

Delayed Canadian Securities Exchange
Other stock markets
 02:54:15 2024-12-12 pm EST 		5-day change 1st Jan Change
0.1700 CAD 0.00% Intraday chart for Entheon Biomedical Corp. +6.25% +70.00%
Dec. 02 Entheon Biomedical Corp. announced that it expects to receive CAD 0.3 million in funding CI
Oct. 24 Entheon Biomedical Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2024 CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Entheon Biomedical Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2024
Oct. 24
 CI
Entheon Biomedical Corp. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2024
Jul. 04
 CI
Entheon Biomedical Corp. Reports Earnings Results for the First Quarter Ended February 29, 2024
Apr. 29
 CI
Entheon Biomedical Corp. Reports Earnings Results for the Full Year Ended November 30, 2023
Mar. 25
 CI
Entheon Biomedical Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2023
23-10-25
 CI
Entheon Biomedical Corp. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2023
23-07-26
 CI
Entheon Biomedical Corp. Reports Earnings Results for the First Quarter Ended February 28, 2023
23-04-28
 CI
Entheon Biomedical Corp. Announces Termination of Consulting Agreement with Cybin
23-04-28
 CI
Entheon Biomedical Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2022
22-10-31
 CI
Entheon Biomedical Corp. Closes Patient Enrolment in its Clinical Research Study EBIQ-101
22-10-05
 CI
Entheon Biomedical Corp. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2022
22-07-26
 CI
Entheon Biomedical Corp. Reports Earnings Results for the First Quarter Ended February 28, 2022
22-04-29
 CI
Entheon Biomedical Corp. Reports Earnings Results for the Full Year Ended November 30, 2021
22-03-30
 CI
Entheon Biomedical Announces Expanded Psychedelics Genetic Test Panel, New Clinical Research Platform
22-03-29
 MT
Entheon Biomedical Corp. Announces Enrollment in Phase 1 Study of DMT
22-03-15
 CI
Entheon Biomedical Corp. Announces EBIQ-101 First-Patient Dose
22-02-24
 CI
Entheon Biomedical Partners with Wavepaths on Upcoming Observational Study
22-02-16
 CI
Entheon Biomedical Corp. Announces the Approval of DMT Clinical Trial
22-02-03
 CI
Entheon Biomedical Corp. Announces the Submission of the Regulatory Package for Its Upcoming Phase 1 Clinical Trial
22-01-06
 CI
Entheon Biomedical Corp. Announces Further Progress on its Nonclinical Program
21-12-16
 CI
Entheon Biomedical Provides Update on Clinical and Preclinical DMT Programs
21-11-24
 CI
Entheon Biomedical Corp. Announces Recruitment Underway in EBIQ-101 Clinical Study
21-11-10
 CI
Entheon Biomedical Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2021
21-10-29
 CI
Entheon Biomedical Corp. Announces Sponsorship of a Clinical Study to Assess the Electroneurophysiologic Effects of Ketamine
21-08-12
 CI
Entheon Biomedical : Buys Lobo Genetics
21-07-30
 MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ENBI Stock
  4. News Entheon Biomedical Corp.
  5. Highlights